NCT00167167已完成不适用
Treatment of Relapsed Leukemia After Allogeneic Bone Marrow Transplantation Using Donor-derived Lymphocytes
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 2
- 主要终点
- Freedom of Disease: Bone marrow histology, cytogenetic analysis and RFLP will be studied. Data will be collected and tabulated.
研究概览
简要总结
In this study our hypothesis is that infusion of donor lymphocyte immune cells from the subject's bone marrow donor will activate the subject's immune system to attack their cancer.
详细描述
We will collect immune cells or lymphocytes from the donor's blood using a cell separator. The blood lymphocytes will be given to the subjects through a catheter. If the subjects have no complications of the first course of infusions, we may decide to give them "lymphocytes" aa second time while subjects are in remission in an attempt to prevent their disease from relapsing. A bone marrow test will be taken prior to infusion of lymphocytes as part of the clinical evaluation to receive this treatment. After lymphocyte infusions, a bone marrow will be examined about every three months for the first year to monitor progress from this therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 1 Year 至 60 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with CML, AML, MDS or ALL relapsed after related or unrelated donor allogeneic marrow transplantation.
- •Patients must be within one year of identification of relapse or if beyond that time period, must have some evidence of donor DNA by RFLP or cytogenetics.
- •Patients may have evidence of relapse based on molecular, cytogenetic or morphologic criteria.
- •CML patients must have cytogenetic evidence of relapse or if Ph negative to start, obvious evidence of relapse other than minimal residual disease.
- •Patients must have <30% marrow blasts on a marrow biopsy performed within two weeks of the first donor lymphocyte infusion.
- •Patients with >30% blasts can become eligible for donor lymphocytes after reinduction with any standard therapy regimen.
- •Patients with AML, MDS or ALL achieving a CR with standard therapy regimens are eligible for this protocol.
- •Patients who relapse with their initial disease or develop a second malignancy after related or unrelated donor allogeneic marrow transplantation with other initial diagnoses (such as but not limited to CLL, lymphoma, myeloma, juvenile CML, sarcoma, breast cancer) may also be included in this protocol. Patients will be eligible with or without other adjunct chemotherapy or radiation therapy. Post-transplant lymphomas (often referred to as EBV-associated lymphomas) will be eligible for donor leukocyte infusions on this protocol. Treatment with donor leukocytes under this protocol is restricted to malignant diseases only. Graft failure or relapse of non-malignant disorders is excluded from receiving donor leukocyte infusions on this protocol. Autologous transplant patients who relapse are not eligible for this protocol. Patients with malignant diseases amenable to other curative therapy are not eligible (i.e. skin cancers).
排除标准
- •Patients with concurrent signs of acute or chronic graft-versus-host disease requiring ongoing treatment at the time of relapse will be ineligible.
- •Patients with >30% marrow blasts at the time of therapy will be ineligible.
- •Patients on prednisone, cyclosporine, Imuran or other immunosuppressive medications are not eligible until these medications are discontinued for at least 2 weeks without a flare of GVHD.
- •CML patients in complete cytogenetic remission who are bcr/abl positive by PCR only are not eligible.
研究组 & 干预措施
BMT patients
Experimental
All patients treated.
干预措施: Donor Lymphocyte Infusion (Procedure)
结局指标
主要结局
Freedom of Disease: Bone marrow histology, cytogenetic analysis and RFLP will be studied. Data will be collected and tabulated.
时间窗: before, at 3 months, 6 months, 9 months and 12 months after donor lymphocyte infusions
次要结局
- Toxicity(during the infusion and immediately thereafter)
- Graft-versus-host disease will be staged using criteria routinely used in allogeneic bone marrow transplant settings and will be tabulated.(ongoing)
- All data concerning acute toxicity including allergic reactions, capillary leak syndrome, and other Grade 4 toxicity will be collected and tabulated.(during the infusion,immediately thereafter, and at 1 month, 3 months, 6 months, 9 months, 1 year and yearly.)
- Marrow Aplasia including duration, treatment and outcomes.(ongoing)
研究者
研究点 (2)
Loading locations...
相似试验
尚未招募
不适用
Immune Reconstitution After Allo-HSCT and BlinatumomabLeukemia, LymphoidNCT06075212Sichuan University20
Unknown
1 期
Treatment of Acute Leukemia Relapse After AllotransplantationAcute Myeloid LeukemiaNCT01369368University of Bergen20
已完成
2 期
Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic TransplantationLeukemiaNCT00548847Emory University15
终止
2 期
Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/LymphomaDiffuse Large Cell LymphomaBurkitts LymphomaT Cell LymphomasAcute Myeloid Leukemia/Acute Lymphoblastic LeukemiaMantle Cell LymphomaNCT01685606Brown University6
终止
1 期
Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell TransplantAcute Myelogenous LeukemiaNon-Hodgkin's LymphomaHodgkin's DiseaseMultiple MyelomaChronic Lymphocytic LeukemiaAcute Lymphoblastic LeukemiaMyelodysplastic SyndromeChronic Myelogenous LeukemiaNCT00674427University of Pennsylvania13